title: Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen)
authors.forename: M
authors.initials: M
authors.lastname: Locatelli
authors.forename: M
authors.initials: M
authors.lastname: Colleoni
authors.forename: C
authors.initials: C
authors.lastname: Noberasco
authors.forename: F
authors.initials: F
authors.lastname: Nolé
authors.forename: L
authors.initials: L
authors.lastname: Orlando
authors.forename: E
authors.initials: E
authors.lastname: Munzone
authors.forename: G
authors.initials: G
authors.lastname: Peruzzotti
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D056486:Chemical and Drug Induced Liver Injury; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008111:Liver Function Tests; D008727:Methotrexate / Q000008:administration & dosage; D012189:Retrospective Studies; D018570:Risk Assessment
chemical_list: D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate